Nordisk

Case Solution for Ethics of Offshoring: Novo Nordisk and Clinical Trials in Emerging Economies

Complete Case details are given below :

Case Name :      Ethics of Offshoring: Novo Nordisk and Clinical Trials in Emerging Economies
Authors :           Klaus Meyer
Source :             Ivey Publishing
Case ID :            909M01
Discipline :        Social Enterprise
Case Length :    13 pages
Solution Sample availability : YES
Plagiarism : NO (100% Original work)
Description for case is given below :
The case outlines the conflicting ethical demands on a Danish pharmaceuticals company, Novo Nordisk, that is operating globally and is aspiring to high standards of corporate social responsibility. A recent report alleges that multinational pharmaceutical companies routinely conduct trials in developing countries under alleged unethical conditions. The company’s director reflects on how to respond to a request from a journalist for an interview. This triggers a discussion on the appropriate ethical principles and how to communicate them. As a company emphasizing corporate responsibility, the interaction with the media presents both opportunities and risks to Novo Nordisk. The case focuses on clinical trials that are required to attain regulatory approval in, for example, Europe and North America, and that are conducted at multiple sites around the world, including many emerging economies. Novo Nordisk has implemented numerous procedures to protect its various stakeholders, yet will this satisfy journalists and non-governmental organizations, and how should the company communicate with these stakeholders?
 
Click Here to place your order
 
OR
Place your order at casesolutionshub (AT)gmail(dot)com if you want to solve above case.
 
Cordially,
Case Solutions Hub

Case Solution for Novo Nordisk: Managing Sustainability at Home and Abroad

Complete Case details are given below :
Case Name :      Novo Nordisk: Managing Sustainability at Home and Abroad
Authors :           Jette Steen Knudsen, Dana Brown
Source :             Ivey Publishing
Case ID :            W12186
Discipline :        General Management
Case Length :    17 pages
Solution Sample availability : YES
Plagiarism : NO (100% Original work)
Description for case is given below :
This case study deals with the opportunities and challenges faced by Danish pharmaceutical company Novo Nordisk with regard to its sustainability approach in China as of 2012. Novo Nordisk is well known for striving to integrate its business activities in a financially, environmentally, and socially responsible way, and many Novo Nordisk employees proudly refer to Novo Nordisk as a “triple bottom line (TBL) company.” Novo Nordisk has been active in China for more than 50 years; however, since the Chinese economy has expanded tremendously, this increase in wealth and a more sedentary Western lifestyle have led to growing problems with obesity. As a result, China’s insulin market is booming. Novo Nordisk therefore faces new challenges concerning how best to organize its TBL program in a way that ensures a comprehensive approach throughout the organization, yet allows Novo Nordisk China to adopt initiatives that fit the Chinese business context. Furthermore, with ever-increasing competition for access to China’s lucrative insulin market, Novo Nordisk’s competitors are also engaging in sustainability, which means that Novo Nordisk must keep innovating to stand out, and must use sustainability as a source of competitive advantage.
 
Click Here to place your order
 
OR
Place your order at casesolutionshub (AT)gmail(dot)com if you want to solve above case.
 
Cordially,
Case Solutions Hub